Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

Abstract Background Bevacizumab combined with chemotherapy produces clinical durable response in 25–30% of recurrent glioblastoma patients. This group of patients has shown improved survival and quality of life. The aim of this study was to investigate changes in gene expression associated with resp...

Full description

Bibliographic Details
Main Authors: Thomas Urup, Line Mærsk Staunstrup, Signe Regner Michaelsen, Kristoffer Vitting-Seerup, Marc Bennedbæk, Anders Toft, Lars Rønn Olsen, Lars Jønson, Shohreh Issazadeh-Navikas, Helle Broholm, Petra Hamerlik, Hans Skovgaard Poulsen, Ulrik Lassen
Format: Article
Language:English
Published: BMC 2017-04-01
Series:BMC Cancer
Subjects:
Anti-angiogenic
RNA-sequencing
Protein kinase C
Reverse mesenchymal transition
TGF-beta
Online Access:http://link.springer.com/article/10.1186/s12885-017-3251-3

Internet

http://link.springer.com/article/10.1186/s12885-017-3251-3

Similar Items